Misoprostol in Obstetrics - DNB Examination Answer (2 + 3 + 5 Marks)

Part A (2 Marks): Pharmacodynamics of Misoprostol

1. Uterus: Misoprostol binds to EP receptors on myometrial smooth muscle cells. This activates phospholipase C signaling, raises intracellular calcium, and promotes myometrial contractions. It also acts on the cervical stroma, stimulating collagenase activity and prostaglandin-mediated remodelling that leads to cervical softening, effacement, and dilatation (cervical ripening).
2. Gastric mucosa: Via EP3 receptors on gastric parietal cells, misoprostol activates the Gi (inhibitory G-protein) pathway, reducing intracellular cyclic AMP and thereby suppressing gastric acid secretion (up to 85-95% inhibition of basal acid secretion). It also stimulates mucin and bicarbonate secretion, providing cytoprotection.
3. Intestine: Increases intestinal motility via smooth muscle EP receptors - accounting for the side effect of diarrhea.

• Rapidly absorbed after oral or vaginal administration; undergoes rapid de-esterification to misoprostol acid (the active metabolite)
• Vaginal administration gives slower absorption, higher peak levels, and a longer duration of action (3-6 hours) compared to oral administration - this makes vaginal route preferred for labour induction
• Peak effect: 60-90 minutes after oral dosing; later with vaginal
• Elimination half-life: 20-40 minutes; excreted mainly in urine

Part B (3 Marks): Indications for Use of Misoprostol in Obstetrics

• Unfavourable cervix at term (Bishop score < 6) requiring induction
• Medical and obstetric indications: gestational hypertension, pre-eclampsia, gestational diabetes, post-dates pregnancy (>41 weeks), PROM, oligohydramnios, IUGR
• Dose: 25 mcg vaginally every 4-6 hours (WHO/ACOG recommended); or 50 mcg in selected cases
• Oral misoprostol (25-50 mcg every 2-4 hours) is also used

• Medical termination of pregnancy (MTP) in combination with mifepristone (200 mg mifepristone followed by misoprostol 800 mcg vaginally/sublingually after 24-48 hours)
• Induction for intrauterine fetal demise (IUFD) - dose depends on gestational age:
  • Uterus < 28 weeks: 200-400 mcg vaginally/orally every 4 hours
  • Uterus > 28 weeks: 25-50 mcg vaginally/orally every 4 hours

• Misoprostol 800 mcg vaginally or 600 mcg sublingually to complete expulsion
• Can be used alone or after mifepristone

• Active management of third stage: misoprostol 600 mcg orally or 800 mcg rectally when oxytocin is unavailable (especially in resource-limited settings)
• Treatment of refractory PPH unresponsive to oxytocin: 800-1000 mcg rectally
• Particularly valuable in community/primary care settings where injectable uterotonics are unavailable

• Cervical priming before first-trimester surgical evacuation (MVA/suction evacuation)
• Cervical ripening before hysteroscopy or other intrauterine procedures

Part C (5 Marks): Monitoring a Primigravida Induced at Full Term with Vaginal Misoprostol

Pre-Induction Assessment

• Confirm gestational age and indication for induction (exclude contraindications)
• Bishop score assessment: Per-vaginal examination to document cervical dilatation, effacement, consistency, position, and fetal station
• Baseline investigations: CBC, blood grouping and cross-matching, coagulation profile if indicated
• Baseline electronic fetal monitoring (CTG): A reactive non-stress test (NST) for at least 20 minutes confirms fetal wellbeing before initiating misoprostol
• Confirm vertex presentation and document fetal position by clinical examination or ultrasound
• Document baseline vital signs: Pulse, BP, temperature, SpO2
• Rule out contraindications: Previous uterine scar (prior CS/myomectomy), placenta previa, active genital herpes, non-vertex presentation, CPD, fetal distress

Monitoring During Induction

• Monitor uterine contractions every 30 minutes after each misoprostol dose
• Note: frequency (normal ≤5 in 10 min), duration (20-60 seconds normal), intensity, and resting tone
• Tachysystole = > 5 contractions in 10 minutes; requires immediate action
• Uterine hyperstimulation = tachysystole + non-reassuring FHR or tetanic contractions (>90 seconds)
• External tocometry (part of CTG) provides continuous monitoring once active labour is established

• Intermittent auscultation: Every 30 minutes in latent phase; every 15 minutes in active first stage; every 5 minutes in second stage (using Pinard stethoscope or Doppler)
• Continuous Electronic Fetal Monitoring (CTG): Preferred throughout induction, especially within the first 2 hours of each misoprostol dose and continuously once active labour begins
• Assess for: baseline rate (normal 110-160 bpm), variability (normal 5-25 bpm), accelerations (reassuring), decelerations (types I/II/III - variable, late, or prolonged indicating fetal compromise)
• Action: Any Category II/III CTG pattern (late decelerations, prolonged bradycardia, reduced variability, sinusoidal pattern) - withhold next dose, apply left lateral positioning, IV hydration, oxygen supplementation, and prepare for emergency delivery if FHR does not improve

• Vaginal examinations every 4 hours (before each repeat dose) to assess:
  • Cervical dilatation, effacement, consistency
  • Fetal descent (station)
  • Presence of caput or moulding
  • Membranes status (intact vs. ruptured)
• Partograph use: Plot cervical dilatation against time; cervicograph should remain to the left of the alert line; crossing the action line mandates reassessment
• Active phase: ≥ 0.5 cm/hour dilatation expected in primigravida; failure to progress triggers augmentation review

• Vital signs (BP, pulse, temperature) every 1-2 hours
• Urine output monitoring; target > 30 mL/hr
• Fluid balance chart - IV line to be maintained
• Monitor for maternal distress: Tachycardia, hypotension, severe pain between contractions (may indicate abruption or scar dehiscence)
• Watch for side effects: Fever (prostaglandin-related), shivering, nausea/vomiting, diarrhea

• Standard regimen: 25 mcg vaginally every 6 hours (maximum 6 doses in 24 hours); or 25 mcg every 4 hours if cervix unfavorable
• Withhold next dose if:
  • Active labour established (≥ 3 contractions/10 min lasting ≥ 45 sec)
  • Non-reassuring FHR pattern
  • Tachysystole or hyperstimulation
  • Cervix ≥ 4 cm dilated

• Maintain a detailed induction record: time of each dose, CTG findings, contractions, VE findings, maternal vitals
• Partograph completion is mandatory

• Once second stage is reached: continuous CTG, BP every 30 min, active pushing instructions
• Prepare for active management of third stage (oxytocin 10 units IM at delivery of anterior shoulder)
• Pediatrician/neonatologist to be informed given induced labour

• Misoprostol = PGE1 synthetic analogue; acts on EP2/EP3 receptors; causes myometrial contractions + cervical ripening
• Obstetric indications span all trimesters: induction at term, MTP, IUFD, missed abortion, PPH management
• Monitoring triad: maternal vitals + uterine contraction pattern + fetal heart rate - best done with continuous CTG and serial VE on partograph
• The single most important monitoring parameter during misoprostol induction is fetal heart rate assessment for hyperstimulation syndrome

Recent 2024-2025 ACOG/RCOG Guidelines on Labour Induction Protocols

1. ACOG Clinical Practice Guideline No. 9: Cervical Ripening in Pregnancy (July 2025)

Misoprostol Recommendations

• Standard dose: 25 mcg vaginally every 3-6 hours - remains the recommended regimen
• This dose is favoured because it achieves effective cervical ripening with a lower rate of tachysystole with FHR changes compared to higher doses
• A 2021 Cochrane review (33 trials, 6,110 participants) confirmed vaginal misoprostol is more effective than oral for time to delivery: vaginal achieved vaginal birth within 24 hours in 60.8% vs 49.3% for oral (RR 0.81, 95% CI 0.68-0.95), though with marginally higher tachysystole

• Acceptable alternative: 25 mcg every 2 hours or 50-100 mcg every 4 hours
• Oral route has less tachysystole with FHR changes (3.9% vs 5.7% vaginal, RR 0.69; but this applies to low-dose ≤50 mcg oral regimens)
• A 2024 cluster RCT (n=2,546) compared oral 100 mcg every 4 hours vs vaginal 25 mcg every 3 hours - comparable vaginal delivery rates (~78%) and identical mean time to delivery (~19.7 hours); tachysystole was actually less with vaginal (3.5% vs 5.9%) in this higher oral dose study

• 2024-2025 data now support outpatient misoprostol ripening (vaginal or oral) in low-risk patients as safe and feasible, reducing inpatient time and total induction-to-delivery intervals without increasing cesarean rates (Vilchez et al., Kandahari et al. 2024; Marsdal et al. 2025)
• Monitoring requirement during outpatient ripening: 2 hours of continuous fetal monitoring after each misoprostol dose

• Concurrent use of vaginal/oral misoprostol with a transcervical Foley balloon is supported - this combination is associated with shorter time to delivery versus either agent alone
• Monitoring: standard misoprostol monitoring; aim for 3-4 contractions per 10 minutes

2. ACOG Clinical Practice Update: Management of Full-Term Nulliparous Individuals (January 2025)

Key Updated Recommendations (ARRIVE Trial Integration)

3. ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management (2024)

• Electronic fetal monitoring (CTG): Continuous EFM throughout induction with pharmacologic agents including misoprostol
• Category I CTG (normal): Continue; Category II (indeterminate): Escalate evaluation; Category III (abnormal): Immediate delivery
• Tachysystole definition (reconfirmed): > 5 contractions in any 10-minute window, averaged over 30 minutes
• Tachysystole with FHR changes: Stop or reduce uterotonus agent; consider tocolysis (terbutaline 0.25 mg SC or sublingual nitroglycerine)
• Amniotomy: Can be offered at ≥ 4 cm dilatation during induction to accelerate progress
• Active phase threshold: ≥ 6 cm now defines active phase (not 4 cm) per ACOG 2014/reaffirmed 2024; adequate time should be allowed before diagnosing arrest disorders

4. NICE Guideline NG207: Induction of Labour (Current - in use 2024-2025)

• Vaginal misoprostol is the preferred method in NICE guidance for induction at term when the cervix is unfavourable
• Dose: 25 mcg vaginally every 6 hours (maximum 50 mcg if slow response, on consultant advice)
• NICE does not recommend oral misoprostol for routine induction at term as first choice (unlike ACOG), though it acknowledges evidence is evolving
• NICE emphasises continuous CTG during induction with prostaglandins
• RCOG Green-top guidelines on induction have not published a new standalone edition in 2024-2025; the most recent update to RCOG's labour induction guidance remains embedded in NICE NG207 endorsement

5. NSW Health Clinical Practice Guide (August 2025) - Summary of Global Consensus

Summary: What Has Changed in 2024-2025

• ACOG CPG No. 9 - Cervical Ripening in Pregnancy (July 2025) [PMID: 40924411]
• ACOG CPU - Management of Full-Term Nulliparous Individuals (Jan 2025) [PMID: 39513607]
• ACOG CPG No. 8 - First and Second Stage Labor Management (Jan 2024)
• NICE NG207 - Induction of Labour (2021, currently active)